Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045218 | 0.95 | KDM1A (0.50) | KDM1ACYP2C19CYP1A2PAOXCA12 | |
| SCHEMBL14619329 | 0.90 | CYP1A2 (0.46) | KDM1ACYP2C19CYP1A2PAOXCA12 | |
| SCHEMBL16573364 | 0.89 | KDM1A (0.39) | KDM1ACYP2C19CYP1A2PAOXCA12 | |
| SCHEMBL16573362 | 0.85 | CA12 (0.46) | KDM1ACYP2C19CYP1A2PAOXCA12 | |
| SCHEMBL27383911 | 0.84 | CYP2C19 (0.48) | KDM1ACYP2C19CYP1A2PAOXS1PR2 | |
| SCHEMBL15787142 | 0.84 | CYP2C19 (0.50) | KDM1ACYP2C19CYP1A2PAOXTSHR | |
| SCHEMBL12157013 | 0.84 | EPHX1 (0.44) | CYP1A2PAOXKDM4EMAPK1HIF1A | |
| SCHEMBL20036359 | 0.84 | EPHX1 (0.44) | CYP1A2PAOXKDM4EMAPK1HIF1A | |
| SCHEMBL22882264 | 0.82 | EPHX1 (0.40) | KDM1ACA2KDM4EMAPK1HIF1A | |
| SCHEMBL24018755 | 0.82 | KDM4E (0.41) | CYP1A2PAOXKDM4EMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2021-04-29 | — | — | US | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-08-29 | — | — | US | disclosed |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | UNIVERSITY OF CANBERRA (AU) | 2019-03-05 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | EpiAxis Therapeutics Pty Ltd. (AU) | 2016-05-26 | — | — | US | disclosed |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | EpiAxis Therapeutics Pty Ltd. (AU) | 2016-05-26 | — | — | US | disclosed |
| WO-2014205511-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | UNIVERSITY OF CANBERRA (AU) | 2014-12-31 | — | — | WO | disclosed |
| US-20120108500-A1 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription | THE J. DAVID GLADSTONE INSTITUTES | 2012-05-03 | — | — | US | disclosed |
| US-20120108500-A1 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription | THE J. DAVID GLADSTONE INSTITUTES | 2012-05-03 | — | — | US | disclosed |
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007021839-A2 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHNS HOPKINS UNIVERSITY (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | KDM1A 1/4885CYP2C19 4039/4885CYP1A2 3343/4885 |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | KDM1A 44/4885CYP2C19 4713/4885CYP1A2 4527/4885 |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | KDM1A 6/4885CYP2C19 4845/4885CYP1A2 4567/4885 |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | KDM1A 6/4885CYP2C19 4845/4885CYP1A2 4567/4885 |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | KDM1A 6/4885CYP2C19 4845/4885CYP1A2 4567/4885 |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | KDM1A 1/4885CYP2C19 4039/4885CYP1A2 3343/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | KDM1A 8/4885CYP2C19 1198/4885CYP1A2 1176/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | KDM1A 44/4885CYP2C19 4713/4885CYP1A2 4527/4885 |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | KDM1A 6/4885CYP2C19 4845/4885CYP1A2 4567/4885 |
| US-20120108500-A1 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription | KDM3B, DNMT3B, KDM1B | KDM1A 18/4885CYP2C19 4726/4885CYP1A2 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.